Document Detail

Efficacy of constant infusion of A-77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, in limiting acute HIV-1 infection in vitro.
MedLine Citation:
PMID:  8585738     Owner:  NLM     Status:  MEDLINE    
A-77003, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, is effective for both acute and chronic infection in vitro and was evaluated clinically by continuous intravenous infusion administration. The minimum effective dose (the concentration required to completely inhibit viral replication) was determined in vitro in a population of uninfected (99%) and HIV-infected (1%) cells exposed to A-77003 by continuous infusion in hollow-fiber bioreactors. The production of infectious HIV and release of p24 antigen from infected cells were completely inhibited in cultures exposed to A-77003 at or above a concentration of 0.5 microM. Measurement of unintegrated HIV-1 DNA synthesis and flow cytometric analysis for cells expressing HIV p24 antigen demonstrated that the spread of HIV to uninfected cells was also blocked at 0.5 microM A-77003. Dose deescalation to 0.25 microM or removal of A-77003 resulted in the limited spread of the virus throughout the culture, the resumption of viral DNA synthesis, and release of p24. HIV produced after exposure to 0.5 microM A-77003 was noninfectious for a period of 72 h after the removal of the drug. Addition of 1 mg of alpha 1-acid glycoprotein per ml to this in vitro system completely ablated the anti-HIV effect of 0.5 microM A-77003. These data suggest that determination of the minimum effective dose under conditions which simulate human pharmacodynamic patterns may be useful in determining the initial dose and schedule for clinical trials. However, other factors, such as serum protein binding, may influence the selection of a therapeutic regimen.
J A Bilello; P A Bilello; J J Kort; M N Dudley; J Leonard; G L Drusano
Related Documents :
21605418 - To use or not to use a condom: a prospective cohort study comparing contraceptive pract...
22210918 - Tlr2 activation enhances hiv nuclear import and infection through t cell activation-ind...
21855518 - Acute hepatitis e infection accounts for some cases of suspected drug-induced liver inj...
22184958 - Consequences of the commercialisation of plasma and blood in china.
20739268 - Prevalence of cardiac diastolic dysfunction in hiv-infected patients: results of the hi...
8276368 - Pretransplantation interferon treatment and recurrence of hepatitis b virus infection a...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Antimicrobial agents and chemotherapy     Volume:  39     ISSN:  0066-4804     ISO Abbreviation:  Antimicrob. Agents Chemother.     Publication Date:  1995 Nov 
Date Detail:
Created Date:  1996-03-20     Completed Date:  1996-03-20     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  0315061     Medline TA:  Antimicrob Agents Chemother     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  2523-7     Citation Subset:  IM; X    
Department of Medicine, Albany Medical College, New York 12208, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiviral Agents / administration & dosage,  pharmacology*
Cell Line
DNA, Viral / biosynthesis
Dose-Response Relationship, Drug
Flow Cytometry
HIV Core Protein p24 / metabolism
HIV Protease Inhibitors / administration & dosage,  pharmacology*
HIV-1 / drug effects*,  physiology
Methylurea Compounds / administration & dosage,  pharmacology*
Orosomucoid / metabolism,  pharmacology
Polymerase Chain Reaction
Pyridines / administration & dosage,  pharmacology*
T-Lymphocytes / virology
Virus Replication / drug effects
Reg. No./Substance:
0/Antiviral Agents; 0/DNA, Viral; 0/HIV Core Protein p24; 0/HIV Protease Inhibitors; 0/Methylurea Compounds; 0/Orosomucoid; 0/Pyridines; 134878-17-4/Abbott 77003

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution met...
Next Document:  Effectiveness of short-course therapy (5 days) with cefuroxime axetil in treatment of secondary bact...